A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum

NCT07337564 | Not Yet Recruiting Phase 2

• 1 other identifier: PG-IIT-SHR1139
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.

Conditions

Pyoderma Gangrenosum

Outcome Measures

Primary Outcomes (1)

• The proportion of subjects whose target PG ulcer achieves complete closure (100% reduction in PG area, PGAR-100) at Week 12.

  Week 12

Secondary Outcomes (3)

• The proportion of subjects whose target PG ulcer achieves 50% closure (50% reduction in PG area, PGAR-50) at Week 12

  Week 12

• The proportion of subjects whose target PG ulcer achieves complete closure (100% reduction in PG area, PGAR-100) at any time point before Week 26;

  up to Week 26

• adverse events(AEs)

  up to Week 48

Study Arms (1)

SHR-1139 injection group

EXPERIMENTAL

Drug: SHR-1139 Injection

Interventions

SHR-1139 Injection DRUG

SHR-1139 Injection

SHR-1139 injection group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, age ≥ 18 years old at the time of signing the informed consent form (ICF).
• Diagnosed with ulcerative PG during screening, and requiring systemic treatment as assessed by the investigator.
• At screening and baseline, there is at least one measurable PG ulcer. If a subject has more than one PG ulcer, the investigator will select the target PG ulcer.
• Subjects voluntarily sign informed consent form (ICF) prior to the commencement of any procedures related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical study protocol.
• Adequate organ and bone marrow function.
• Female subjects of childbearing potential or male subjects whose partners are females of childbearing potential shall have no plans for childbearing, sperm/egg donation from the time of signing the informed consent form until 72 weeks after the last dose, and shall voluntarily adopt effective contraceptive measures (including their partners). Female subjects must have a negative pregnancy test result during the screening period and before randomization and drug administration, and must not be breastfeeding.

You may not qualify if:

• At screening, the clinical manifestations are other ulcers or other similar skin lesions caused by non-PG diseases;
• There is a significant medical history or underlying disease that affects safety.
• A history of allergy to the study drug or any component of the study drug before screening.
• A history of alcohol abuse or illegal drug abuse within one year before screening;
• Having donated approximately 500 mL of blood within 8 weeks before baseline or having plans to donate blood during the study.
• Other circumstances that the investigator judges may affect the evaluation of the safety and efficacy of the study drug.

Sponsors & Collaborators

• Shandong First Medical University: lead

Study Sites (1)

Dermatology Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, 250000, China

Location

MeSH Terms

Conditions

Pyoderma Gangrenosum

Condition Hierarchy (Ancestors)

Pyoderma; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vascular; Skin Ulcer

Central Study Contacts

Furen Zhang

CONTACT

15854179852; splcsy@126.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2025
• First Posted: January 13, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): June 1, 2028
• Last Updated: January 13, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)